Literature DB >> 21196340

STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis.

Karishma Mehra1, Mitra Mehrad, Geng Ning, Ronny Drapkin, Frank D McKeon, Wa Xian, Christopher P Crum.   

Abstract

The events leading to the most common and most lethal ovarian carcinoma - high grade serous carcinoma - have been poorly understood. However, the detailed pathologic study of asymptomatic women with germ-line BRCA 1 or BRCA2 (BCRA+) mutations has unearthed an early malignancy, serous tubal intraepithelial carcinomas (STIC), which has linked many peritoneal and ovarian serous carcinomas to the fimbria. The distinction between high-grade serous and endometrioid carcinomas continues to narrow, with shared alterations in expression of pTEN, PAX2 and p53. Moreover, the discovery of clonal alterations in p53 in benign tubal epithelium, - p53 signatures - has established a foundation for a serous cancer precursor in the fimbria. We have expanded this concept to include a generic secretory cell outgrowth (SCOUT) in the fallopian tube that is associated with altered PAX2 expression. As the repertoire of gene alterations is expanded and its link to serous carcinogenesis clarified, a cogent pathway to high-grade Mullerian carcinomas will emerge. This will challenge conventional thinking about ovarian carcinogenesis but will provide a new template for studies of ovarian cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196340     DOI: 10.2741/e275

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  37 in total

1.  Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal?

Authors:  T J Herzog; H E Dinkelspiel
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

Review 2.  [Histopathology and clinical aspects of extrauterine pregnancy].

Authors:  L-C Horn; S Opitz; R Handzel; C E Brambs
Journal:  Pathologe       Date:  2018-09       Impact factor: 1.011

3.  [The 2016 update of the S3 guideline for malignant tumours of the ovary : Role of pathology in diagnosis, therapy and clinical management of epithelial tumours].

Authors:  A Staebler; D Mayr
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

4.  Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Authors:  Kala Visvanathan; Russell Vang; Patricia Shaw; Amy Gross; Robert Soslow; Vinita Parkash; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

Review 5.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

6.  Tubal origin of ovarian low-grade serous carcinoma.

Authors:  Chenglu Chen; Jie Li; Guang Yao; Setsuko K Chambers; Wenxin Zheng
Journal:  Am J Clin Exp Obstet Gynecol       Date:  2013-12-15

Review 7.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 8.  Molecular approaches to personalizing management of ovarian cancer.

Authors:  R C Bast
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

Review 9.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

10.  Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

Authors:  Yiying Wang; Li Li; Yue Wang; Sarah Ngocvi Tang; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.